BC Pet Owners Have a New Weapon Against Dog Breath

Canadian-Made StrixNB(TM) Scientifically Proven to Improve Oral Health

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/22/13 -- A brand new, Canadian-made invention is officially in British Columbia now to help improve companion animals' oral hygiene and prevent bad breath. Kane Biotech Inc. (TSX VENTURE:KNE) is pleased to mark the official introduction of its StrixNB pet oral care product to the BC market today at Market Hill Animal Hospital in Vancouver.

"This is an important step for us as we begin selling this revolutionary new product across Western Canada. We've had a few weeks to introduce the product to veterinarians, now it's time to let pet owners know about StrixNB," said Jason Leibert, Vice President, Business Development of Kane Biotech. "The experience in our home market of Manitoba is that pet owners want StrixNB as soon as they learn about it, as it helps solve a basic problem: it is scientifically proven to benefit a pet's oral health and reduce bad breath. Pet owners and veterinary clinics in Manitoba are making StrixNB the go to pet oral care product."

Through Pacific Veterinary Sales, the company has been introducing StrixNB to veterinarians across BC, Alberta and Saskatchewan for the past few weeks. Today's official launch is one in a series of events designed to raise awareness of this Canadian innovation.

StrixNB is a new, safe and effective drinking water additive scientifically formulated to help maintain and promote good dental and oral hygiene in pets. It is unique because it works against bacteria associated with dental disease by altering the mouth's environment. It breaks through dental biofilm - a highly structured, matrix-embedded microbial population - making bacteria accessible for eradication by a microbial agent.

"It's important for pet owners to take care of their pets' dental health. We recommend that StrixNB be part of a complete oral care program, in addition to daily brushing, dental diets and chews," said Dr. Reza Rashidi DVM, veterinarian with Market Hill Animal Hospital. "It has been scientifically proven to help fight dental disease. A happy side effect is that it also fights bad breath. We're pleased to be able to offer it to our customers and will be interested in seeing what kind of impact it can have on our patients' oral care."

Studies have shown that StrixNB can have a positive impact on the teeth and gum line of dogs, while softening plaque to make it easier to remove. Dental diseases cause pain and discomfort and can lead to other problems. Some dental diseases, such as periodontal disease, can create bacteria able to travel into your pet's bloodstream, affecting the lungs, heart, kidneys, liver and nervous system.

StrixNB is available for sale through veterinary clinics. Pacific Veterinary Sales is the distributor for the product in Western Canada. "My dog is a Jack Russell and they are notorious for bad breath. I started using StrixNB and noticed a huge improvement in her breath," said Ken Kasdorf, Director of Sales of Pacific Veterinary Sales. The product enjoyed breakout success when it first went on sale in Manitoba earlier this year. More than 70 per cent of the province's vet clinics signed up to carry the product after its initial launch.

About StrixNB™

StrixNB is a safe and effective drinking water additive to help maintain and promote good dental and oral hygiene for companion animals. StrixNB is xylitol-free, made using 100% human food grade ingredients and registered with the Interim Notification Program of Health Canada for Low Risk Veterinary Health Products (NN.1Q11).

For more information about our product, please visit our website at www.strixnb.com or like us on Facebook at www.facebook.com/StrixNB.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

StrixNB™, DispersinB® and Aledex® are registered trademarks of Kane Biotech Inc. All Rights Reserved 2013

Kane Biotech Inc.
Jason Leibert
Vice President, Business Development
(204) 453-1301 x 305
(204) 474-7552 (FAX)
jleibert@kanebiotech.com
www.kanebiotech.com
Dooley Communications
Adam Dooley
President
(204) 415-0688 or Cell: (204) 291-4092
adooley@dooleycommunications.ca

Source: Kane Biotech Inc.

Released May 22, 2013